Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
32 Leser
Artikel bewerten:
(0)

Health Care Equipment and Supplies Stocks Technical Insight -- Research on Abbott Laboratories, Accuray, Medtronic, and Varian Medical Systems

LONDON, June 13, 2014 /PRNewswire/ --

On Thursday, June 12, 2014, the NASDAQ Composite ended at 4,297.63, down 0.79%, the Dow Jones Industrial Average edged 0.65% lower, to finish the day at 16,734.19, and the S&P 500 closed at 1,930.11, down 0.71%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 688.58, down 0.56%, while the index has advanced 1.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Abbott Laboratories (NYSE: ABT), Accuray Inc. (NASDAQ: ARAY), Medtronic Inc. (NYSE: MDT) and Varian Medical Systems Inc. (NYSE: VAR). Free technical research on ABT, ARAY, MDT and VAR can be downloaded upon signing up at:

http://www.investor-edge.com/3753-register

Abbott Laboratories' stock edged 0.48% lower, to close the day at $39.81. The stock recorded a trading volume of 6.51 million shares, close to its three months average volume of 6.66 million shares. The stock oscillated between $39.66 and $40.04 during the session. Over the last one month and over the past three months, Abbott Laboratories' shares have gained 1.38% and 0.38%, respectively. Additionally, the stock has advanced 3.86% since the start of this year. The stock is trading above its 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $38.97 is greater than its 200-day moving average of $37.57. Additionally, the stock traded at a PE ratio of 22.58 and has a Relative Strength Index (RSI) of 56.82. Sign up today to read free research on ABT at:

http://www.investor-edge.com/3753-ABT-13Jun2014.pdf

On Thursday, Accuray Inc.'s stock recorded a trading volume of 0.42 million shares, lower than its three months average volume of 0.78 million shares. The stock ended the day at $8.79, which was 1.38% above its previous day's closing of $8.67, and registered an intraday range of $8.52 and $8.82. Accuray Inc.'s shares have advanced 3.29% in the previous three trading sessions and 6.16% in the last one month. Additionally, from the beginning of 2014, the company's stock has gained an upside of 1.03%. The company's stock is trading above its 50-day and 200-day moving averages of $8.53 and $8.35, respectively. Furthermore, shares of the company have an RSI of 54.44. Sign up today to read free research on ARAY at:

http://www.investor-edge.com/3753-ARAY-13Jun2014.pdf

Medtronic Inc.'s stock finished the Thursday's session 0.62% lower at $60.79. A total of 3.52 million shares were traded, which was below its three months average volume of 4.36 million shares. The stock moved between $60.62 and $61.32 during the session. Although, Medtronic Inc.'s shares have lost 0.33% in the last one month, it has advanced 1.60% in the previous three months and 5.92% on YTD basis. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $60.14 is greater than its 200-day moving average of $57.59. Medtronic Inc.'s stock traded at a PE ratio of 16.13 and has an RSI of 52.90. Sign up today to read free research on MDT at:

http://www.investor-edge.com/3753-MDT-13Jun2014.pdf

On Thursday, shares in Varian Medical Systems Inc. traded between $80.53 and $81.72 before ending the session 0.45% higher at $81.69. Varian Medical Systems Inc.'s stock reported a trading volume of 0.43 million shares, below its three months average volume of 0.67 million shares. Shares of the company traded at a PE ratio of 20.75. Varian Medical Systems Inc.'s shares have fallen by 0.07% in the previous three trading sessions and 2.04% in the last one month. However, the stock has advanced 5.15% since start of this year. The stock is trading above its 50-day and 200-day moving averages of $81.58 and $78.95, respectively. Moreover, shares of the company have an RSI of 46.66. Sign up today to read free research on VAR at:

http://www.investor-edge.com/3753-VAR-13Jun2014.pdf

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.